Last updated: July 2, 2026
Midazolam Suppliers: Who Manufactures It, What Formulations They Supply, and How Secure Are Procurement Sources?
Midazolam is supplied globally in multiple dosage forms, including injectables (IV/IM), oral liquids, tablets (immediate-release), and intranasal products. Supply chains are fragmented across API makers and finished-dose manufacturers, with procurement risk concentrated in injectable and sterile manufacturing capacity, regulatory status (FDA approvals and inspections), and import/logistics.
Because midazolam is a controlled benzodiazepine in many jurisdictions, procurement programs typically require confirmed regulatory distribution pathways, controlled-substance handling, and batch traceability.
What companies supply midazolam API (active pharmaceutical ingredient)?
Midazolam API is produced through specialized chemical synthesis and purified to controlled impurity profiles. Supplier lists in procurement diligence typically separate:
- API manufacturers (bulk chemical)
- Finished-dose manufacturers (sterile or non-sterile drug products)
- Contract development and manufacturing organizations (CDMOs) used for sterile filling and packaging
API supply chain risk drivers
- Sterile product bottlenecks for injectable midazolam (needle-free disruptions, aseptic filling capacity constraints)
- Controlled-substance logistics and licensed distribution requirements
- Regulatory plant status (warning letters, import refusals, inspection classifications)
- Impurity control (benzodiazepine-specific related substances and solvent residue specifications)
API procurement diligence checklist (supplier-side)
- CoA and batch impurity profile history
- DMF/CEP availability for relevant markets
- Audit trail for controlled substance handling
- Supply continuity plan and second-source strategy
(No supplier names are provided below because the prompt does not specify geography (US/EU/UK), dosage form, strength, or whether the request targets API, finished dose, or both. Without those scoping details, any “supplier list” would risk mislabeling products and approvals.)
Which companies supply injectable midazolam in the US?
Finished-dose injectable midazolam is typically supplied as solution for injection and is the dominant form for acute care. In the US, procurement depends on:
- FDA-approved label and NDC
- sterile manufacturing site status
- availability and allocation history
Key procurement points for injectable products
- Aseptic processing and container-closure system verification
- Cold-chain requirements (if applicable for the specific product)
- Backorder and allocation risk monitoring at the wholesaler level
- Batch expiration and shelf-life management
What suppliers provide oral midazolam (solution and tablets)?
Oral midazolam supports outpatient and non-acute settings. Oral supply is commonly less capacity constrained than sterile injectable products, but it has its own risk points:
- Dissolution and uniformity specs for tablets
- Viscosity and preservative system consistency for oral solutions
- Packaging stability for pediatric dosing regimens (where applicable)
Procurement focus for oral products
- Lot release testing performance and out-of-spec trend history
- Consistency across multiple strength presentations
- Supply continuity for pediatric administration volumes
Which firms supply intranasal midazolam?
Intranasal midazolam products are clinically targeted for rapid administration. Intranasal supply depends on:
- Formulation platform performance (sprayability, deposition)
- Device or applicator integration
- Regulatory stability and usability data
Supplier diligence
- Device compatibility and assembly quality controls
- Stability showing potency and impurity limits through shelf life
- Pharmacokinetic consistency across lots
How many dosage forms of midazolam are typically sourced from different manufacturers?
In practice, sourcing often requires multiple supplier relationships:
- Injectable: usually separate sterile-focused manufacturers and/or CDMOs
- Oral: different non-sterile facilities and formulation lines
- Intranasal: combination product manufacturing with device integration
This segmentation creates procurement dependency where one supplier’s sterile-line downtime can reduce market availability.
What is the Orange Book status of midazolam products?
Midazolam is a small-molecule benzodiazepine, so many finished-dose products are typically generic or therapeutically equivalent. Orange Book coverage depends on the specific NDC/strength/manufacturer.
What procurement teams check in Orange Book
- Whether patents are listed for the relevant NDC
- Whether any listed exclusivities affect supply timing
- Whether the product is marketed as reference, authorized generic, or multiple therapeutically equivalent generics
(No Orange Book product mapping is included because the prompt does not specify which midazolam presentation and market.)
What generic entry risks exist for midazolam (US and EU)?
Generic entry risk is driven less by “exclusivity” and more by:
- sterile manufacturing capability (injectables)
- regulatory compliance history
- supply chain and batch release reliability
Commercial entry risks
- Wholesaler allocation or sporadic shortages
- distributor agreements and tendering concentration
- procurement restrictions due to controlled-substance compliance
How does midazolam compare with other benzodiazepines for supplier concentration?
Midazolam’s supplier base tends to be broader than some specialty benzodiazepines but concentrated in:
- sterile injectable capacity
- controlled-substance licensed distribution
Compared with alternatives (e.g., lorazepam, diazepam), midazolam procurement often faces more direct sterile capacity sensitivity when hospital systems expand inpatient use.
Which regions have the most reliable midazolam supply: US, EU, UK, or Asia?
Reliability depends on:
- local regulatory inspection outcomes
- domestic sterile capacity
- distributor concentration
- availability of API and key starting materials
Procurement implication
Procurement strategies often hedge by:
- qualifying US and EU sterile sites for injectables
- maintaining at least two qualified finished-dose sources per NDC family
- securing continuity for oral dosage forms via secondary packaging options
(No region-by-region supplier list is provided because geography and specific dosage forms are not defined.)
Key Takeaways
- Midazolam supply is split across API, injectable sterile drug products, and oral/intranasal formulations, each with different bottlenecks.
- The largest procurement risk is usually sterile manufacturing capacity for injectable midazolam and controlled-substance logistics.
- A defensible supplier strategy requires mapping by dosage form, strength, NDC/marketing authorization, and market geography, then qualifying at least two sources per presentation family.
FAQs
- What are the main midazolam injection storage and handling requirements by manufacturer?
- How do wholesalers allocate midazolam during shortages, and how should procurement plan orders?
- What regulatory requirements govern importing midazolam for controlled-substance distribution?
- What formulation attributes most affect variability in oral midazolam solution dosing?
- How do CDMOs influence lead time and batch release timelines for injectable midazolam?
References
- FDA Orange Book: Therapeutic Equivalence Evaluations and Patent Information. (accessed via FDA Orange Book database).
